{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:13:15Z","timestamp":1790691195585,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T00:00:00Z","timestamp":1482278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiac fibrosis is a common finding in patients with chronic kidney disease. Here, we investigate the cardio-renal effects of theracurmin, a novel formulation of the polyphenolic compound curcumin, in a rat model of chronic kidney disease. Briefly, Sprague-Dawley rats were randomized to undergo sham or subtotal nephrectomy (SNx) surgery. At 3 weeks post surgery, SNx animals were further randomized to received theracurmin via once daily oral gavage or vehicle for 5 consecutive weeks. At 8 weeks post surgery, cardiac function was assessed via echocardiography and pressure volume loop analysis, followed by LV and renal tissue collection for analysis. SNx animals developed key hallmarks of renal injury including hypertension, proteinuria, elevated blood urea nitrogen, and glomerulosclerosis. Renal injury in SNx animals was also associated with significant diastolic dysfunction, macrophage infiltration, and cardiac NLRP3 inflammasome activation. Treatment of SNx animals with theracurmin improved structural and functional manifestations of cardiac injury associated with renal failure and also attenuated cardiac NLRP3 inflammasome activation and mature IL-1\u03b2 release. Taken together, our findings suggest a significant role for the NLRP3 inflammasome in renal injury-induced cardiac dysfunction and presents inflammasome attenuation as a unique strategy to prevent adverse cardiac remodeling in the setting of chronic kidney disease.<\/jats:p>","DOI":"10.1038\/srep39551","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T10:26:08Z","timestamp":1482315968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction"],"prefix":"10.1038","volume":"6","author":[{"given":"Antoinette","family":"Bugyei-Twum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Abadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golam","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"BFsrep39551_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351, 1296\u20131305 (2004).","journal-title":"N Engl J Med"},{"key":"BFsrep39551_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/ncpneph0673","volume":"3","author":"RW Schrier","year":"2007","unstructured":"Schrier, R. W. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 3, 637 (2007).","journal-title":"Nat Clin Pract Nephrol"},{"key":"BFsrep39551_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000063551","volume":"20","author":"K Tyralla","year":"2002","unstructured":"Tyralla, K. & Amann, K. Cardiovascular changes in renal failure. Blood Purif 20, 462\u2013465 (2002).","journal-title":"Blood Purif"},{"key":"BFsrep39551_CR4","doi-asserted-by":"crossref","unstructured":"Tyralla, K. & Amann, K. Morphology of the heart and arteries in renal failure. Kidney Int Suppl, S80\u201383 (2003).","DOI":"10.1046\/j.1523-1755.63.s84.1.x"},{"key":"BFsrep39551_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2011.01043.x","volume":"243","author":"JC Leemans","year":"2011","unstructured":"Leemans, J. C., Cassel, S. L. & Sutterwala, F. S. Sensing damage by the NLRP3 inflammasome. Immunol Rev 243, 152\u2013162 (2011).","journal-title":"Immunol Rev"},{"key":"BFsrep39551_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1172\/JCI12089","volume":"107","author":"VY Melnikov","year":"2001","unstructured":"Melnikov, V. Y. et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 107, 1145\u20131152 (2001).","journal-title":"J Clin Invest"},{"key":"BFsrep39551_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1172\/JCI0215623","volume":"110","author":"VY Melnikov","year":"2002","unstructured":"Melnikov, V. Y. et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 110, 1083\u20131091 (2002).","journal-title":"J Clin Invest"},{"key":"BFsrep39551_CR8","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1681\/ASN.2005030236","volume":"16","author":"CR Parikh","year":"2005","unstructured":"Parikh, C. R., Abraham, E., Ancukiewicz, M. & Edelstein, C. L. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 16, 3046\u20133052 (2005).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep39551_CR9","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2010020143","volume":"21","author":"A Vilaysane","year":"2010","unstructured":"Vilaysane, A. et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21, 1732\u20131744 (2010).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep39551_CR10","first-page":"244","volume":"1","author":"NJ Garg","year":"2011","unstructured":"Garg, N. J. Inflammasomes in cardiovascular diseases. Am J Cardiovasc Dis 1, 244\u2013254 (2011).","journal-title":"Am J Cardiovasc Dis"},{"key":"BFsrep39551_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"P Anand","year":"2007","unstructured":"Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol Pharm 4, 807\u2013818 (2007).","journal-title":"Mol Pharm"},{"key":"BFsrep39551_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1248\/bpb.34.660","volume":"34","author":"H Sasaki","year":"2011","unstructured":"Sasaki, H. et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34, 660\u2013665 (2011).","journal-title":"Biol Pharm Bull"},{"key":"BFsrep39551_CR13","doi-asserted-by":"publisher","first-page":"F1146","DOI":"10.1152\/ajprenal.90732.2008","volume":"296","author":"SS Ghosh","year":"2009","unstructured":"Ghosh, S. S. et al. Curcumin ameliorates renal failure in 5\/6 nephrectomized rats: role of inflammation. Am J Physiol Renal Physiol 296, F1146\u20131157 (2009).","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFsrep39551_CR14","doi-asserted-by":"publisher","first-page":"H975","DOI":"10.1152\/ajpheart.00154.2010","volume":"299","author":"SS Ghosh","year":"2010","unstructured":"Ghosh, S. S. et al. Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol 299, H975\u2013984 (2010).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFsrep39551_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10557-015-6581-x","volume":"29","author":"S Hernandez-Resendiz","year":"2015","unstructured":"Hernandez-Resendiz, S. et al. Cardioprotection by curcumin post-treatment in rats with established chronic kidney disease. Cardiovasc Drugs Ther 29, 111\u2013120 (2015).","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFsrep39551_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/j.1523-1755.2005.00290.x","volume":"67","author":"CK Fujihara","year":"2005","unstructured":"Fujihara, C. K., Velho, M., Malheiros, D. M. & Zatz, R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67, 1913\u20131924 (2005).","journal-title":"Kidney Int"},{"key":"BFsrep39551_CR17","doi-asserted-by":"publisher","first-page":"F1810","DOI":"10.1152\/ajprenal.00521.2006","volume":"292","author":"CK Fujihara","year":"2007","unstructured":"Fujihara, C. K., Malheiros, D. M. & Zatz, R. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5\/6 ablation model. Am J Physiol Renal Physiol 292, F1810\u20131818 (2007).","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFsrep39551_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/ki.2008.528","volume":"75","author":"F Teles","year":"2009","unstructured":"Teles, F. et al. Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int 75, 72\u201379 (2009).","journal-title":"Kidney Int"},{"key":"BFsrep39551_CR19","doi-asserted-by":"crossref","unstructured":"Parving, H. H., Andersen, A. R., Hommel, E. & Smidt, U. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension 7, II114\u2013117 (1985).","DOI":"10.1161\/01.HYP.7.6_Pt_2.II114"},{"key":"BFsrep39551_CR20","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","volume":"110","author":"FW Asselbergs","year":"2004","unstructured":"Asselbergs, F. W. et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110, 2809\u20132816 (2004).","journal-title":"Circulation"},{"key":"BFsrep39551_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921\u2013927 (2004).","journal-title":"Circulation"},{"key":"BFsrep39551_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/eci.12035","volume":"43","author":"S Selvarajah","year":"2013","unstructured":"Selvarajah, S. et al. Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. Eur J Clin Invest 43, 198\u2013207 (2013).","journal-title":"Eur J Clin Invest"},{"key":"BFsrep39551_CR23","doi-asserted-by":"crossref","unstructured":"Lopez, B., Gonzalez, A., Hermida, N., Laviades, C. & Diez, J. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl, S19\u201323 (2008).","DOI":"10.1038\/ki.2008.512"},{"key":"BFsrep39551_CR24","first-page":"S62","volume":"58","author":"K Amann","year":"2002","unstructured":"Amann, K. & Tyralla, K. Cardiovascular changes in chronic renal failure--pathogenesis and therapy. Clin Nephrol 58 Suppl 1, S62\u201372 (2002).","journal-title":"Clin Nephrol"},{"key":"BFsrep39551_CR25","doi-asserted-by":"crossref","unstructured":"Morimoto, T., W. H., Sunagawa, Y. et al. Highly absorptive curcumin improves left ventricula diastolic function regardless of blood pressure in hypertensive patients. J Am Coll Cardiol. 59(13s1):E987 (2012).","DOI":"10.1016\/S0735-1097(12)60988-7"},{"key":"BFsrep39551_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1440-1797.2006.00541.x","volume":"11","author":"P Stenvinkel","year":"2006","unstructured":"Stenvinkel, P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 11, 36\u201341 (2006).","journal-title":"Nephrology (Carlton)"},{"key":"BFsrep39551_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urology.2005.09.028","volume":"67","author":"N Kuwabara","year":"2006","unstructured":"Kuwabara, N. et al. Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology 67, 440\u2013446 (2006).","journal-title":"Urology"},{"key":"BFsrep39551_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10, 417\u2013426 (2002).","journal-title":"Mol Cell"},{"key":"BFsrep39551_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu Rev Immunol 27, 229\u2013265 (2009).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep39551_CR30","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1084\/jem.183.3.949","volume":"183","author":"A Kumar","year":"1996","unstructured":"Kumar, A. et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183, 949\u2013958 (1996).","journal-title":"J Exp Med"},{"key":"BFsrep39551_CR31","doi-asserted-by":"publisher","first-page":"H1025","DOI":"10.1152\/ajpheart.00795.2013","volume":"306","author":"S Toldo","year":"2014","unstructured":"Toldo, S. et al. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 306, H1025\u20131031 (2014).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFsrep39551_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10557-012-6389-x","volume":"26","author":"S Toldo","year":"2012","unstructured":"Toldo, S. et al. Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse. Cardiovasc Drugs Ther 26, 273\u2013276 (2012).","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFsrep39551_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00011-013-0625-0","volume":"62","author":"BW Van Tassell","year":"2013","unstructured":"Van Tassell, B. W., Seropian, I. M., Toldo, S., Mezzaroma, E. & Abbate, A. Interleukin-1beta induces a reversible cardiomyopathy in the mouse. Inflamm Res 62, 637\u2013640 (2013).","journal-title":"Inflamm Res"},{"key":"BFsrep39551_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/nep.12279","volume":"19","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. & Kompa, A. R. A practical guide to subtotal nephrectomy in the rat with subsequent methodology for assessing renal and cardiac function. Nephrology (Carlton) 19, 552\u2013561 (2014).","journal-title":"Nephrology (Carlton)"},{"key":"BFsrep39551_CR35","doi-asserted-by":"publisher","first-page":"H1699","DOI":"10.1152\/ajpheart.00577.2005","volume":"290","author":"KA Connelly","year":"2006","unstructured":"Connelly, K. A. et al. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol 290, H1699\u20131705 (2006).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFsrep39551_CR36","first-page":"H1416","volume":"274","author":"D Georgakopoulos","year":"1998","unstructured":"Georgakopoulos, D. et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 274, H1416\u20131422 (1998).","journal-title":"Am J Physiol"},{"key":"BFsrep39551_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/002215549904700113","volume":"47","author":"HA Lehr","year":"1999","unstructured":"Lehr, H. A., van der Loos, C. M., Teeling, P. & Gown, A. M. Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 47, 119\u2013126 (1999).","journal-title":"J Histochem Cytochem"},{"key":"BFsrep39551_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.RES.83.6.594","volume":"83","author":"H Kai","year":"1998","unstructured":"Kai, H. et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 83, 594\u2013601 (1998).","journal-title":"Circ Res"},{"key":"BFsrep39551_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cardiores.2007.06.022","volume":"76","author":"KA Connelly","year":"2007","unstructured":"Connelly, K. A. et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 76, 280\u2013291 (2007).","journal-title":"Cardiovasc Res"},{"key":"BFsrep39551_CR40","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/ki.1997.214","volume":"51","author":"LL Wu","year":"1997","unstructured":"Wu, L. L. et al. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 51, 1553\u20131567 (1997).","journal-title":"Kidney Int"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep39551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39551","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:55:06Z","timestamp":1672901706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep39551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep39551"],"URL":"https:\/\/doi.org\/10.1038\/srep39551","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,21]]},"assertion":[{"value":"5 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39551"}}